Patterns of care for brachytherapy in Japan
- PMID: 38151923
- PMCID: PMC10959427
- DOI: 10.1093/jrr/rrad099
Patterns of care for brachytherapy in Japan
Abstract
This study aimed to assess the current state of brachytherapy (BT) resources, practices and resident education in Japan. A nationwide survey was undertaken encompassing 177 establishments facilitating BT in 2022. Questionnaires were disseminated to each BT center, and feedback through online channels or postal correspondence was obtained. The questionnaire response rate was 90% (159/177), and every prefecture had a response in at least one center. The number of centers in each prefecture ranged from 0.6 to 3.6 (median: 1.3) per million population. The annual number of patients in each center ranged from 0 to 272 (median: 31). While most prefectures provided intracavitary (IC) BT for gynecological cancers and interstitial (IS) BT for prostate cancer, only one-third of the prefectures provided IS BT for cancer sites other than the prostate. The institutional image-guided BT implementation rate was 71%. IC and IS BT was performed for 15.4% of IC BT cases of gynecological cancer. Only 47% of the BT training centers answered that they could provide adequate training in BT for residents. The most common reason for this finding was the insufficient number of patients in each center. The results show that, although BT has achieved uniformity in terms of facility penetration, new technologies are not yet widespread enough. Furthermore, IS BT, which requires advanced skills, is limited to a few BT centers, and considerable number of BT training centers do not have sufficient caseloads to provide the necessary experience for their residents.
Keywords: brachytherapy; medical resources; national survey; patterns of care; resident education.
© The Author(s) 2023. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.
Conflict of interest statement
Naoya Murakami reported grants from Elekta K.K., and honoraria from Medicaline K.K., AstraZeneca plc, and Chiyoda Technol Corporation. Ken Yoshida reported advisory role of Chiyoda Technol Corporation. Hideyuki Sakurai reported grants from Hitachi Co. Ltd. The other authors have no conflicts of interest to declare regarding this study.
Figures
References
-
- Guedea F. Perspectives of brachytherapy: patterns of care, new technologies, and “new biology”. Cancer Radiother 2014;18:434–6. - PubMed
-
- Guedea F, Ventura M, Mazeron JJ. et al. Patterns of care for brachytherapy in Europe: facilities and resources in brachytherapy in the European area. Brachytherapy 2008;7:223–30. - PubMed
-
- Guedea F, Venselaar J, Hoskin P. et al. Patterns of care for brachytherapy in Europe: updated results. Radiother Oncol 2010;97:514–20. - PubMed
-
- Hannoun-Levi JM, Hennequin C, Pommier P. et al. National breast cancer brachytherapy survey in France: results and perspectives in 2009. Cancer Radiother 2010;14:176–82. - PubMed
